FY2023 EPS Estimates for Stevanato Group S.p.A. (NYSE:STVN) Decreased by KeyCorp

Stevanato Group S.p.A. (NYSE:STVN) – KeyCorp reduced their FY2023 earnings per share estimates for Stevanato Group in a research note issued on Tuesday, October 31st. KeyCorp analyst P. Knight now expects that the company will post earnings per share of $0.61 for the year, down from their prior forecast of $0.66. KeyCorp has a “Overweight” rating and a $37.00 price target on the stock. The consensus estimate for Stevanato Group’s current full-year earnings is $0.61 per share. KeyCorp also issued estimates for Stevanato Group’s Q4 2023 earnings at $0.19 EPS, FY2024 earnings at $0.72 EPS and FY2025 earnings at $0.83 EPS.

A number of other research firms also recently issued reports on STVN. Morgan Stanley reduced their price objective on Stevanato Group from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Stephens began coverage on Stevanato Group in a research note on Monday, September 25th. They issued an “overweight” rating and a $33.00 price objective on the stock. Jefferies Financial Group downgraded Stevanato Group from a “buy” rating to a “hold” rating and cut their target price for the company from $39.00 to $29.00 in a research report on Wednesday. CJS Securities began coverage on Stevanato Group in a research report on Tuesday, September 19th. They set an “outperform” rating and a $36.00 target price on the stock. Finally, Wells Fargo & Company boosted their target price on Stevanato Group from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 31st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Stevanato Group has a consensus rating of “Moderate Buy” and an average target price of €32.67 ($34.75).

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €26.67 ($28.37) on Friday. The business has a fifty day simple moving average of €30.56 and a two-hundred day simple moving average of €30.22. The company has a current ratio of 1.36, a quick ratio of 0.88 and a debt-to-equity ratio of 0.11. Stevanato Group has a 12 month low of €13.71 ($14.59) and a 12 month high of €36.30 ($38.62). The firm has a market capitalization of $7.88 billion, a P/E ratio of 45.20, a P/E/G ratio of 3.97 and a beta of 0.87.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC increased its position in shares of Stevanato Group by 3.4% in the first quarter. Lazard Asset Management LLC now owns 6,366,679 shares of the company’s stock valued at $128,097,000 after buying an additional 210,007 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Stevanato Group by 19.7% in the third quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after acquiring an additional 746,136 shares during the last quarter. Thrivent Financial for Lutherans acquired a new stake in shares of Stevanato Group in the first quarter worth approximately $45,382,000. Clearbridge Investments LLC boosted its stake in shares of Stevanato Group by 1.7% in the second quarter. Clearbridge Investments LLC now owns 1,665,860 shares of the company’s stock worth $53,941,000 after acquiring an additional 27,190 shares during the last quarter. Finally, Sands Capital Management LLC acquired a new stake in shares of Stevanato Group in the second quarter worth approximately $40,997,000. 10.90% of the stock is currently owned by hedge funds and other institutional investors.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.